Xlife Sciences AG - Asset Resilience Ratio
Xlife Sciences AG (XLS) has an Asset Resilience Ratio of 0.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Xlife Sciences AG carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Xlife Sciences AG's Asset Resilience Ratio has changed over time. See XLS net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Xlife Sciences AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see XLS market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF51.55K | 0.01% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF51.55K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Xlife Sciences AG maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Xlife Sciences AG Industry Peers by Asset Resilience Ratio
Compare Xlife Sciences AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Xlife Sciences AG (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Xlife Sciences AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.02% | CHF99.03K ≈ $125.20K |
CHF540.37 Million ≈ $683.18 Million |
-0.02pp |
| 2023-12-31 | 0.04% | CHF218.71K ≈ $276.51K |
CHF511.99 Million ≈ $647.30 Million |
0.00pp |
| 2022-12-31 | 0.05% | CHF221.04K ≈ $279.45K |
CHF490.23 Million ≈ $619.78 Million |
-0.36pp |
| 2021-12-31 | 0.41% | CHF1.96 Million ≈ $2.47 Million |
CHF480.06 Million ≈ $606.93 Million |
-2.13pp |
| 2020-12-31 | 2.53% | CHF4.70 Million ≈ $5.95 Million |
CHF185.68 Million ≈ $234.75 Million |
+0.88pp |
| 2019-12-31 | 1.65% | CHF2.54 Million ≈ $3.21 Million |
CHF154.02 Million ≈ $194.72 Million |
-- |
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more